• Users Online: 598
  • Print this page
  • Email this page
Year : 2021  |  Volume : 25  |  Issue : 2  |  Page : 129-130

Use of intramuscular triamcinolone acetonide in intermediate responders to janus kinase inhibition for alopecia areata: Case report

Department of Dermatology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA

Correspondence Address:
Dr. Crystal Aguh
JHOC 8th Floor, 601 N., Caroline Street, Baltimore, Maryland 21231
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jdds.jdds_38_20

Rights and Permissions

Janus kinase (JAK) inhibitors have been identified as an effective treatment option for severe alopecia areata (AA), but response is variable among patients. Intramuscular triamcinolone acetonide (IMTA), which has a greater bioavailability than other forms of steroids, has been used effectively to treat refractory AA with very few side effects. However, the use of IMTA in combination with JAK inhibitors is not well characterized. We present two patients with severe patch type AA and alopecia totalis who failed to achieve substantial regrowth after at least 6 months of oral tofacitinib and were treated with a single dose of IMTA 60 mg. Both patients had more than 50% increase in hair regrowth in areas of hair loss that had persisted on tofacitinib with no reported adverse effects.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded44    
    Comments [Add]    

Recommend this journal